The FDA said Tuesday it’s pairing up with the data company Aetion to research Covid-19 complications and what types of medicines virus patients are taking, which could help researchers learn more about which treatments are effective.

The Food and Drug Administration is already using its internal drug monitoring system called Sentinel to learn more about Covid-19 responses nationwide. The partnership with Aetion will add to that data to “contribute to the scientific evaluation of potential diagnostics and interventions for COVID-19,” Amy Abernethy, the agency’s principal deputy commissioner of food and drugs, said in a statement.

Read more.